Protein / target

Gastric inhibitory polypeptide

Encoded byGIPP09681Homo sapiensSwiss-Prot

UniProt: P09681 Ensembl: ENSG00000159224 HGNC: HGNC:4270 NCBI Gene: 2695

Small-molecule tractable

Druggability

Structure with Ligand

Research papers

Protein at a glance

Biological role

Gastric inhibitory polypeptide receptor binding

Strongest disease association

Hypertension

Via encoding gene GIP · Genetic evidence · score 0.46

Research activity

Actively researched

66 papers · latest 2026

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Potent stimulator of insulin secretion and relatively poor inhibitor of gastric acid secretion

Subcellular location

Secreted

Domains and Gene Ontology detail (14)

Gene Ontology

Cendoplasmic reticulum lumen
Cextracellular region
Cextracellular space
Csecretory granule lumen
Fgastric inhibitory polypeptide receptor binding
Fglucagon receptor binding
Fhormone activity
Padenylate cyclase-activating G protein-coupled receptor signaling pathway
Pgastric inhibitory peptide signaling pathway
Pregulation of fatty acid biosynthetic process
Pregulation of insulin secretion
Presponse to glucose

153 aa · 17 kDa

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Lipid & lipoprotein metabolismGO

View supporting evidence

Lipid & lipoprotein metabolism

·regulation of fatty acid biosynthetic process

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene GIP

Gene-level evidence surfaced through the gene GIPthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Hypertension

0.47Limited support

Genetic evidence dominant · Open Targets 0.29

Diabetes Mellitus, Type 2

0.46Limited support

Genetic evidence dominant · Open Targets 0.25

Metabolic Diseases

0.41Limited support

Genetic evidence dominant · Open Targets 0.25

Hyperlipidemias

0.38Limited support

Genetic evidence dominant · Open Targets 0.23

Obesity disorder

0.31Limited support

Genetic evidence dominant · Open Targets 0.16

View evidence synthesis (5)

HypertensionLimited support

0.47

agreement 0.33–0.61

Genetic97%Literature3%

Open Targets aggregate 0.29 · 2 independent evidence families

Diabetes Mellitus, Type 2Limited support

0.46

agreement 0.32–0.59

Genetic72%Literature28%

Open Targets aggregate 0.25 · 2 independent evidence families

Metabolic DiseasesLimited support

0.41

agreement 0.28–0.55

Genetic93%Literature7%

Open Targets aggregate 0.25 · 2 independent evidence families

HyperlipidemiasLimited support

0.38

agreement 0.24–0.52

Genetic98%Literature2%

Open Targets aggregate 0.23 · 2 independent evidence families

Obesity disorderLimited support

0.31

agreement 0.17–0.45

Genetic72%Literature28%

Open Targets aggregate 0.16 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations

Hypertension0.29

Diabetes Mellitus, Type 20.25

Metabolic Diseases0.25

Hyperlipidemias0.23

Neurodegenerative Diseases0.23

Obesity disorder0.16

Prostate carcinoma0.15

Essential Hypertension0.15

Tractability

Small molecules — Emerging

Feasibility evidence (structure with ligand) — no clinical-stage drug of this modality recorded.